1. Poorkiani M, Hazrati M, Abbaszadeh A, Jafari P, Sadeghi M, Dejbakhsh T, et al. Does a rehabilitation program improve quality of life in breast cancer patients? Payesh. 2010, 9(1): 61-8.
|
2. Sajadian A, Kaviani A, Montazeri A, Haji Mahmodi M, Ebrahimi M, Samie F, et al. The use of complementary and alternative therapies in cancer patients. Payesh. 2004, 4(3): 197-205.
|
|
3. MardaniHamule M, ShahrakiVahed A. Relationship between mental health and quality of life in cancer patients. JSSU. 2010; 18 (2) :111-7.
|
|
4. Yavari P, Mehrabi U, Pour-Hoseingholi M A. Knowledge and practice of women toward breast self-examination: A case-control study. J Ardabil Univ Med Sci. 2005; (4) : 371-7.
|
|
5. Sharafi A, Khoshgard K, Nikoofar A. Measurement of the absorbed dose by Bladder and Rectum in the radiation therapy of Prostate cancer by Yhermoluminescent Dosimetry Method. RJMS. 2009; 16 (64): 7-13.
|
|
6. Clay C, Perera S, Wagner J M, Miller M E, Nelson, Greenspan S L. Physical function in men with prostate cancer on androgen deprivation therapy. Physical Therapy. 2007; 87(10): 1325-33.
|
|
7. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005; 55(2): 74-108
|
|
8. Newton R U, Taaffe D R, Spry N, Gardiner R A, Levin G, Wall B, et al. Phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer. 2009; 9: 210.
|
|
9. Mohammadi Falah M R, Jafari S, Alizade M, Mokhtari M R. The effect of intravesical BCG therapy on serum PSA level. Urmia Medical Journal. 2008, 2(19): 152-7.
|
|
10. Morgentaler A. Testosterone, Prostate cancer: What are the risks for middle-aged men? UrolClin North Am. 2011; 38(2): 119-24.
|
|
11.American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park). 2000; 14: 267–72.
|
|
12. Goldenberg S L, Koupparis A, Robinson M E. Differing levels of testosterone and the prostate: A physiological interplay. Nat Rev Urol. 2011; 31(7): 365-77
|
|
13. Smith M R, Finkelstein J S, McGovern F J, Zietman A L, Fallon M A, Schoenfeld D A, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87(2): 599-603.
|
|
14.Greenspan S L, Coates P, Sereika S M, Nelson J B, Trump D L, Resnick N M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90(12): 6410-7.
|
|
15. Galva˜o D A, Newton R U. Review of exercise intervention studies in cancer patients. J Clin Oncol. 2005; 23(4): 899-909.
|
|
16. Sharifi N, Gulley J L, Dahut W L. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238–44.
|
|
17. Segal R J, Reid R D, Courneya K S, Malone S C, Parliament M B, Scott C G, et al. Resistance exercise in men receiving androgen deprivation therapy for Prostate cancer. J Clin Oncol. 2003; 21(9):1653-9.
|
|
18. Galvão D A, Nosaka K, Taaffe D R, Spry N, Kristjanson L J, McGuigan M R, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006; 38(12): 2045-52.
|
|
19. Culos Reed S N, Robinson J L, Lau H, O’Connor K, Keats M R. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007; 29(1): 118-27.
|
|
20. Galvao D A, Taaffe D R, Spry N, Joseph D, Newton R U. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for Prostate cancer without bone metastases: A randomized controlled trial. J Clin Oncol. 2010; 28(2): 340-7.
|
|
21. Hansen P A, Dechet C B, Porucznik C A, LaStayo P C. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: A pilot study. PMR. 2009; 1(11): 1019-24.
|
|
22. Sale D G. Neural adaptation to resistance training. Med Sci Sports Exerc. 1988; 20(5 Suppl): 135-45.
|
|
23. Saylor P J, Smith M R. Metabolic complications of androgen deprivation therapy for Prostate cancer. J Urol. 2009; 181(5): 1998-2006. Discussion; 2007-2008.
|
|
24. Galvao D A, Nosaka K, Taaffe D R, Peake J, Spry N, Suzuki K, et al. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis. 2008; 11(2): 160-5.
|
|
25. Galvão D A, Spry N A, Taaffe D R, Newton R U, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008; 102(1): 44-7.
|
|
26. Galvao D A, Taaffe D R, Spry N, Newton R U. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4): 340-6.
|
|
27. Disibio G, French S W. Metastatic patterns of cancer: Results from a large autopsy study. Arch Pathol Lab Med. 2008; 132(6): 931-9.
|
|
28. Hakkinen K, Pakarinen A, Kraemer W J, Newton R U, Alen M. Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle-aged and elderly men and women. J Gerontol A Biol Sci Med Sci. 2000; 55(2): 95-105.
|
)